Objective: To explore the association of 12-lipoxygenase (LOX12) Arg261Gln polymorphism with the risk of hepatic carcinoma in Chinese population.
Methods: A total of 280 cases of hepatic carcinoma and 560 frequency-matched controls were recruited from January 2008 to December 2012 at Hebei United University Affiliated Hospital. The method of PCR-restriction fragment length polymorphism (RFLP) was employed to genotype LOX12 Arg261Gln polymorphism. And odds ratios (OR) and 95% confidence intervals (CI) were calculated with a model of unconditional Logistic regression.
Results: The allelic frequency for LOX12 Arg261Gln was significantly higher in hepatic carcinoma cases than that in controls (0.563 vs 0.437). For the control group, the three genotypes of LOX12 Arg/Arg, Arg/Gln and Gln/Gln were 24.3% (136/560), 52.9% (296/560) and 22.8% (128/560) respectively. For the hepatic carcinoma group, these three genotypes were 19.1% (53/278), 49.3% (137/278) and 31.6% (88/278) respectively. Logistic regression analysis showed that, compared with 261 Arg/Arg genotype carriers, the subjects with 261Gln/Gln had increased risks for hepatic carcinoma (OR = 1.83, 95%CI:1.18-2.84). When stratified by smoking status, the 261Gln/Gln carriers had an increased risk of developing hepatic carcinoma (OR = 2.23, 95%CI:1.16-4.26) among smokers, but not among non-smokers.
Conclusion: LOX12 Arg261Gln polymorphism is associated with the susceptibility to hepatic carcinoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Fe3O4-viral-like Mesoporous Silica Nanoparticle(Fe3O4-vMSN)-Sustained Release of Lenvatinib for Targeted Treatment of Hepatocellular Carcinoma.
Curr Cancer Drug Targets
January 2025
Department of Clinical Laboratory, Gongli Hospital of Shanghai Pudong New Area, Shanghai, 200135, China.
Background: Lenvatinib is an oral tyrosine kinase inhibitor that selectively inhib-its receptors involved in tumor angiogenesis and tumor growth. It is an emerging first-line treatment agent for hepatocellular carcinoma (HCC). However, there is no intravenous ad-ministration of Lenvatinib.
View Article and Find Full Text PDFTRIPLET combined with microwave ablation: A novel treatment for advanced hepatocellular carcinoma.
World J Gastrointest Oncol
January 2025
Senior Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People's Liberation Army General Hospital, Beijing 100091, China.
This editorial comments on a study by Zuo . The focus is on the efficacy of hepatic arterial infusion chemotherapy combined with camrelizumab and apatinib (the TRIPLET regimen), alongside microwave ablation therapy, in treating advanced hepatocellular carcinoma (HCC). The potential application of this combination therapy for patients with advanced HCC is evaluated.
View Article and Find Full Text PDFAdvancing treatment strategies: Insights from network meta-analysis of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.
World J Gastrointest Oncol
January 2025
Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung City 404328, Taiwan.
This study examines the pivotal findings of the network meta-analysis of Zhou , which evaluated the efficacy of hepatic arterial infusion chemotherapy and combination therapies for advanced hepatocellular carcinoma (HCC). This meta-analysis suggests that therapeutic combinations have greater efficacy than do standard treatments. The article highlights the key insights that have the potential to shift current clinical practice and enhance outcomes for patients with advanced HCC.
View Article and Find Full Text PDFAdvanced hepatocellular carcinoma treatment strategies: Are transarterial approaches leading the way?
World J Gastrointest Oncol
January 2025
Department of General and Pediatric Surgery, Bolzano Central Hospital - SABES, Bolzano 39100, Trentino-Alto Adige, Italy.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with advanced stages posing significant treatment challenges. Although hepatic arterial infusion chemotherapy (HAIC) has emerged as a promising modality for treating advanced HCC, particularly in Asian clinical practice, its adoption in Western medicine remains limited due to a lack of large-scale randomized controlled trials. This editorial reviews and comments on the meta-analysis conducted by Zhou , which evaluates the efficacy and safety of HAIC and its combination strategies for advanced HCC.
View Article and Find Full Text PDFTargeted gene sequencing and bioinformatics analysis of patients with gallbladder neuroendocrine carcinoma: A case report.
World J Gastrointest Oncol
January 2025
Department of Medical College, Jinan University, Guangzhou 510000, Guangdong Province, China.
Background: Gallbladder neuroendocrine carcinoma (NEC) represents a subtype of gallbladder malignancies characterized by a low incidence, aggressive nature, and poor prognosis. Despite its clinical severity, the genetic alterations, mechanisms, and signaling pathways underlying gallbladder NEC remain unclear.
Case Summary: This case study presents a rare instance of primary gallbladder NEC in a 73-year-old female patient, who underwent a radical cholecystectomy with hepatic hilar lymphadenectomy and resection of liver segments IV-B and V.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!